IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
DESIGN AND FORMULATION OF THERMOREVERSIBLE HYDROGEL CONTAINING CAPECITABINE AS CONTROLLED RELEASE DOSAGE FORM TO TREAT CANCER.

Author: HARSH VARIA, DR. RAJESH K.S
Abstract: The purpose of present research work was to design and formulation of capecitabine controlled release dosage form to achieve a prolonged therapeutic effect with constantly releasing medication over an extended period of time by administration of a single dose. The present study aims to treat colorectal cancer with improved patient compliance. The selected drug, capecitabine is designed to release therapeutic concentration over a long period of time and termed as controlled release dosage form. Capecitabine is readily absorbed from gastrointestinal tract. Hence controlled release delivers maximum drug in colon lowering dosing frequency. Procured drug was identified as Capecitabine by solubility study, melting point study, FT-IR study and calibration curve development. Thermoreversible hydrogel containing capecitabine as a drug, thermoreversible polymer (PF-127) and viscosity enhancing agent (HPMC E-50 LV) were prepared by cold method. The optimization of formulations was performed by 32 factorial design using Design Expert 9.0.4 software. The formulations were evaluated for visual appearance, clarity, gelling capacity, pH, gelling temperature, viscosity, drug content and in-vitro release study, which shown satisfactory results. The results of tests of parenteral formulations indicated that they were free from particulate matters and sterilized completely. The results of stability study indicated that there was no significant change in gelling temperature, viscosity and in-vitro drug release after one month. Thus, thermoreversible hydrogel was successfully prepared and evaluated to provide better prospects for parenteral delivery of capecitabine in treatment of colorectal cancer.
Keyword: Thermoreversible hydrogel, Colorectal cancer, Capecitabine
DOI: https://doi.org/10.31838/ijpr/2019.11.01.034
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
Pharmacovigilance: Current Scenario and Emerging Trends

National Conference sponsored by GUJCOST on 03.08.2019 at SNLPCP, Umrakh

Download Brochure
News & Events
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477